NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
5 trialsNCT01277757 2018-12-19
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01776008 2018-05-08
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01319539 2017-08-30
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01240941 2013-08-20
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn